EP1558232A2 - Treating obesity with selective androgen receptor modulators - Google Patents
Treating obesity with selective androgen receptor modulatorsInfo
- Publication number
- EP1558232A2 EP1558232A2 EP03777596A EP03777596A EP1558232A2 EP 1558232 A2 EP1558232 A2 EP 1558232A2 EP 03777596 A EP03777596 A EP 03777596A EP 03777596 A EP03777596 A EP 03777596A EP 1558232 A2 EP1558232 A2 EP 1558232A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- nhcor
- conhr
- cor
- snr
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000849 selective androgen receptor modulator Substances 0.000 title claims abstract description 397
- 208000008589 Obesity Diseases 0.000 title claims abstract description 102
- 235000020824 obesity Nutrition 0.000 title claims abstract description 84
- 229940083324 Selective androgen receptor modulator Drugs 0.000 claims abstract description 391
- 238000000034 method Methods 0.000 claims abstract description 149
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 94
- 150000003839 salts Chemical class 0.000 claims abstract description 92
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 86
- -1 hydrate Chemical class 0.000 claims abstract description 83
- 102000016267 Leptin Human genes 0.000 claims abstract description 81
- 108010092277 Leptin Proteins 0.000 claims abstract description 81
- 239000013078 crystal Substances 0.000 claims abstract description 78
- 229940039781 leptin Drugs 0.000 claims abstract description 78
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims abstract description 78
- 239000000651 prodrug Substances 0.000 claims abstract description 77
- 229940002612 prodrug Drugs 0.000 claims abstract description 77
- 229940127557 pharmaceutical product Drugs 0.000 claims abstract description 75
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 63
- 239000000203 mixture Substances 0.000 claims abstract description 61
- 206010020772 Hypertension Diseases 0.000 claims abstract description 56
- 230000003247 decreasing effect Effects 0.000 claims abstract description 56
- 239000002207 metabolite Substances 0.000 claims abstract description 39
- 235000019789 appetite Nutrition 0.000 claims abstract description 33
- 230000036528 appetite Effects 0.000 claims abstract description 33
- 230000001965 increasing effect Effects 0.000 claims abstract description 32
- 230000004580 weight loss Effects 0.000 claims abstract description 30
- 230000011759 adipose tissue development Effects 0.000 claims abstract description 29
- 210000003205 muscle Anatomy 0.000 claims abstract description 29
- 208000019622 heart disease Diseases 0.000 claims abstract description 28
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 28
- 230000001737 promoting effect Effects 0.000 claims abstract description 25
- 208000023516 stroke disease Diseases 0.000 claims abstract description 23
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 23
- 235000013861 fat-free Nutrition 0.000 claims abstract description 18
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 18
- 210000000130 stem cell Anatomy 0.000 claims abstract description 18
- 230000024245 cell differentiation Effects 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 355
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 246
- 229910052794 bromium Inorganic materials 0.000 claims description 245
- 229910052801 chlorine Inorganic materials 0.000 claims description 245
- 229910052731 fluorine Inorganic materials 0.000 claims description 244
- 229910052740 iodine Inorganic materials 0.000 claims description 243
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 146
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 97
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 96
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 95
- 125000000217 alkyl group Chemical group 0.000 claims description 95
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 claims description 72
- 125000004122 cyclic group Chemical group 0.000 claims description 71
- 125000003118 aryl group Chemical group 0.000 claims description 66
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 54
- 229910052760 oxygen Inorganic materials 0.000 claims description 48
- 229910052717 sulfur Inorganic materials 0.000 claims description 48
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 125000001188 haloalkyl group Chemical group 0.000 claims description 27
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims description 26
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 23
- 230000007423 decrease Effects 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 70
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 20
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 claims 1
- YUCFVHQCAFKDQG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH] YUCFVHQCAFKDQG-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 21
- 230000002265 prevention Effects 0.000 abstract description 6
- 125000001424 substituent group Chemical group 0.000 description 41
- 208000035475 disorder Diseases 0.000 description 31
- 102000001307 androgen receptors Human genes 0.000 description 25
- 108010080146 androgen receptors Proteins 0.000 description 25
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 17
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000004069 differentiation Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000003098 androgen Substances 0.000 description 12
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 230000037406 food intake Effects 0.000 description 9
- 235000012631 food intake Nutrition 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 125000004982 dihaloalkyl group Chemical group 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 229940030486 androgens Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 125000004385 trihaloalkyl group Chemical group 0.000 description 5
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010058359 Hypogonadism Diseases 0.000 description 4
- 208000029725 Metabolic bone disease Diseases 0.000 description 4
- 206010049088 Osteopenia Diseases 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 201000001880 Sexual dysfunction Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000001195 anabolic effect Effects 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229960000997 bicalutamide Drugs 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000019771 cognition Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000024963 hair loss Diseases 0.000 description 4
- 230000003676 hair loss Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 208000001076 sarcopenia Diseases 0.000 description 4
- 231100000872 sexual dysfunction Toxicity 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001548 androgenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000011167 hydrochloric acid Nutrition 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000013116 obese mouse model Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 2
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000070928 Calligonum comosum Species 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100031775 Leptin receptor Human genes 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000003277 amino group Chemical class 0.000 description 2
- 239000003936 androgen receptor antagonist Substances 0.000 description 2
- 238000009165 androgen replacement therapy Methods 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004634 feeding behavior Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940124011 Androgen receptor agonist Drugs 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HPFVBGJFAYZEBE-XNBTXCQYSA-N [(8r,9s,10r,13s,14s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3CC2)C)CC[C@@]11C)CC1OC(=O)CCC1CCCC1 HPFVBGJFAYZEBE-XNBTXCQYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- MRKZAZMYXYSBDG-UHFFFAOYSA-N cyclopentyl propanoate Chemical compound CCC(=O)OC1CCCC1 MRKZAZMYXYSBDG-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000002434 gonadorelin derivative Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 201000010930 hyperostosis Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000270 methylestrenolone Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 229940096973 urethral suppository Drugs 0.000 description 1
- 239000006217 urethral suppository Substances 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- This invention relates to the prevention and treatment of obesity. More particularly, this invention relates to a method of a) treating, preventing, suppressing, inhibiting, or reducing obesity; b) promoting, increasing or facilitating weight loss; c) decreasing, suppressing, inhibiting or reducing appetite; d) altering the body composition; e) altering lean body mass or fat firee body mass; f) converting fat to lean muscle; g) treating, preventing, suppressing, inhibiting, or reducing an obesity- associated metabolic disorder, for example hypertension, osteoarthritis, Type II diabetes mellitus, increased blood pressure, stroke, or heart disease; h) decreasing, suppressing, inhibiting or reducing adipogenesis; i) altering stem cell differentiation; and/or j) altering the level of leptin; comprising administering a therapeutically effective amount of a selective androgen receptor modulator and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate,
- Obesity is not only a nutritional disorder in Western societies, it is also a serious health concern because of its association with adult-onset diabetes, hypertension, and heart disease (Grundy, 1990, Disease-a-Month 36:645-696). In addition, obesity is currently described by World Health Organization (WHO) as an epidemic in many industrialized nations. While there is evidence to suggest that body weight was physiologically regulated, the molecular mechanism has remained elusive. However, animal studies have produced several mouse strains that contain single-gene mutations, resulting in an obese phenotype. One such recessive mutation is manifested in the ob/ob mice, and it is referred to as the obese (ob) mutation.
- WHO World Health Organization
- the ob gene product (also known as Leptin), is a major adipocyte-derived hormone that is involved in the regulation of food intake and energy expenditure.
- mice when normal mice received leptin, they also ate less than the untreated controls. More importantly, Campfield et al. (1995, Science 269:546-549) injected leptin directly into lateral ventricle, and observed a reduction in the animals' food intake, suggesting that leptin acts on central neuronal networks to regulate feeding behavior and energy balance. Thus, this result provides evidence that the leptin receptor (also known as OB-R) is expressed by cells in the brain. Additionally, several studies have shown that ob gene expression is actually increased in obese humans (Considine et al., 1995, J. Clin. Invest. 95:2986-2988; Lonnquist etal., 1995, Nature Med. 1:950; Hamilton etal., 1995, Nature Med. 1:953).
- leptin is effective at controlling weight loss, food intake, and energy expenditure
- modulating and/or controlling the levels of leptin is a useful therapeutic approach in treating preventing, inhibiting or reducing the incidence of obesity in subjects suffering from obesity.
- Controlling the level of leptin may result in a loss of appetite, a reduction of food intake, and an increase in energy expenditure in the subj ect, and thus may contribute to the control and treatment of obesity.
- Obesity if left unabated, can have dire health consequences, such as adult-onset diabetes (Type II diabetes), hypertension, heart disease, osteoarthritis, increased blood pressure, increased incidence of stroke, and accelerated morbidity and mortality.
- Traditional approaches are urgently needed at both the basic science and clinical levels to treat obesity.
- This invention relates to the prevention and treatment of obesity. More particularly, this invention relates to a method of a) treating, preventing, suppressing, inhibiting, or reducing obesity; b) promoting, increasing or facilitating weight loss; c) decreasing, suppressing, inhibiting or reducing appetite; d) altering the body composition; e) altering lean body mass or fat free body mass; f) converting fat to lean muscle; g) treating, preventing, suppressing, inhibiting, or reducing an obesity-associated metabolic disorder, for example hypertension, osteoarthritis, Type II diabetes mellitus, increased blood pressure, stroke, or heart disease; h) decreasing, suppressing, inhibiting or reducing adipogenesis; i) altering stem cell differentiation; and/or j) altering the level of leptin; comprising administering a therapeutically effective amount of a selective androgen receptor modulator and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable
- this invention relates to a method of treating a subject suffering from obesity, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metaboUte, pharmaceutically acceptable salt, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to treat obesity in the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of preventing, suppressing, inhibiting or reducing the incidence of obesity in a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metaboUte, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to prevent, suppress, inhibit or reduce the incidence of obesity in the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of promoting, increasing or facilitating weight loss in a subj ect, comprising the step of administering to the subj ect a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N- oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to promote, increase or faciUtate weight loss in the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of decreasing, suppressing, inhibiting or reducing appetite of a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to decrease, suppress, inhibit or reduce the appetite of the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of altering the body composition of a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and or its analog, derivative, isomer, metaboUte, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to alter the body composition of the subject.
- SARM selective androgen receptor modulator
- alteringthe body composition comprises altering the lean body mass, the fat firee body mass of the subject, or a combination thereof.
- this invention relates to a method of altering lean body mass or fat firee body mass of a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metaboUte, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N- oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to alter the lean body mass or fat free body mass of the subject.
- SARM selective androgen receptor modulator
- this invention relates to amethod of converting fatto lean muscle in a subject, comprising the step of adi inistering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metaboUte, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to convert fat to lean muscle in the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of treating an obesity- associated metaboUc disorder in a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metaboUte, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N- oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to treat the obesity-associated metaboUc disorder in the subj ect.
- SARM selective androgen receptor modulator
- this invention relates to a method of preventing, suppressing, inhibiting or reducing an obesity-associated metabolic disorder in a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/oir its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to prevent, suppress, inhibit or reduce the obesity-associated metabolic disorder in the subject.
- SARM selective androgen receptor modulator
- the obesity-associated metaboUc disorder is hypertension, hi another embodiment, the disorder is osteoarthritis. In another embodiment, the disorder is Type II diabetes meUitus. In another embodiment, the disorder is increased blood pressure. In another embodiment, the disorder is stroke. In another embodiment, the disorder is heart disease.
- this invention relates to a method of decreasing, suppressing, inhibiting or reducing adipogenesis in a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metaboUte, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to decrease, suppress, inhibit or reduce adipogenesis in the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of altering stem ceU differentiation in a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to alter stem ceU differentiation in the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of altering the level of leptin in a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metaboUte, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to alter the level of leptin in the subj ect.
- SARM selective androgen receptor modulator
- altering the level of leptin comprises decreasing the level of leptin in the subject.
- this invention relates to a method of decreasing, suppressing, inhibiting or reducing the level of leptin in a subject, comprising the step of ad hiistering to the subj ect a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to decrease, suppress, inhibit or reduce the level of leptin in the subject.
- SARM selective androgen receptor modulator
- G is O or S
- X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
- T is OH, OR, -NHCOCHs, or NHCOR
- Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
- Y is CF 3 , F, I, Br, Cl, CN, CR 3 or SnR 3 ;
- Q is aUcyl, F, Cl, Br, I, CF 3 , CN CR 3 , SnR 3 , NR 2 , NHCOCBj, NHCOCFs, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR HSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR, NCS, SCN, NCO, OCN; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:
- R is aUcyl, haloalkyl, dihaloalkyl, trihaloaU yl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH; and
- Ri is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ; or its analog, derivative, isomer, metaboUte, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of the SARM compound, or any combination thereof.
- X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
- Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
- Y is CF 3 , F, I, Br, Cl, CN, CR 3 or SnR 3 ;
- Q is alkyl, F, Cl, Br, I, CF 3 , CN CR 3 , SnR 3 , NR 2 ,
- R is alkyl, haloaU yl, dihaloaUcyl, trihaloaU yl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH; or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of the SARM compound, or any combination thereof.
- X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
- G is O or S; Ri is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ; T is OH, OR, -NHCOCHa, or NHCOR; R is alkyl, haloalkyl, dihaloalkyl, trihaloaUcyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aiyl, phenyl, F, Cl, Br, I, alkenyl or OH; A is a ring selected f om:
- B is a ring selected from:
- Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
- Y is CF 3 , F, I, Br, Cl, CN CR 3 or SnR 3 ;
- Qi and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSRNHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR, NCS, SCN, NCO, OCN,
- Q 3 and Q 4 are independently of each other a hydrogen, aUcyl, F, Cl, Br, I, CF 3 , CN CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 ,NHCSCF 3 , NHCSRNHSO 2 CH 3 ,NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR, NCS, SCN, NCO or OCN; Wi is O, NH, NR, NO or S; and W 2 is N or NO; or its analog, derivative, isomer, metaboUte, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of the SARM compound, or any combination thereof.
- X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
- G is O or S
- T is OH, OR, -NHCOCHs, or NHCOR;
- R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
- Ri is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
- R 2 is F, Cl, Br, I, CH 3 , CF 3 , OH, CN, NO 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, aUcyl, arylaU yl, OR, NH 2 , NHR, NR 2 or SR;
- R 3 is F, Cl, Br, I, CN, NO 2 , COR, COOH, CONHR, CF 3 , SnR 3 , or R 3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:
- Z is NO 2 , CN, COR, COOH, or CONHR;
- Y is CF 3 , F, Br, Cl, I, CN, or SnR 3 ;
- Q is H, alkyl, F, Cl, Br, I, CF 3 , CN CR 3 , SnR 3 , NR 2 ,
- R 2 is F, Cl, Br, I, CH 3 , CF 3 , OH, C ⁇ , ⁇ O 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, alkyl, aryla&yl, OR, NH 2 , NHR, NR 2 or SR;
- R 3 is F, Cl, Br, I, CN, NO 2 , COR, COOH, CONHR, CF 3 , SnR , or R 3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:
- R is alkyl, haloalkyl, dihaloaUcyl, trihaloaU yl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, aUcenyl or OH;
- Z is NO 2 , CN, COR, COOH, or CONHR;
- Y is CF 3 ⁇ F, Br, Cl, I, CN, or SnR 3 ;
- Q is H, ah yl, F, Cl, Br, I, CF 3 , CN CR 3 , SnR 3 , NR 2 , NHCOCHj, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF3, NHCSRNHSO 2 CH 3 , NHSO 2 R, OH, OR, COR, OCOR, OSO 2 R, SO 2 R, SR
- the SARM is an androgen receptor agonist. In another embodiment, the SARM is an androgen receptor antagonist.
- the present invention provides a safe and effective method of treating, preventing, suppressing, inhibiting or reducing the incidence of obesity and/or an obesity- associated metaboUc disorder, controlling appetite and promoting weight loss, altering body composition including lean body mass and fat firee body mass, converting fat to lean muscle, blocking adipogenesis, altering stem ceU differentiation, and is particularly useful in treating subjects suffering from symptoms and signs caused by obesity, excessive appetite and overweight, and obesity-associated metaboUc disorders such as hypertension, osteoarthritis, Type II diabetes meUitus, increased blood pressure, stroke, and heart disease.
- Figure 1 Effect of Compound VI on lean body mass in female rats. Rats were left untreated (intact) or ovariectomized (OVX), and were treated with 0, 0.1, 0.3, 0.5, 0.75 1.0 and 3.0 mg/day of compound VI, or treated with DHT or bicalutamide. The percent change in lean body mass is depicted in Figure 1 A. The absolute values of lean body mass (in grams) are depicted in Figure IB.
- Figure 2 Effect of Compound VI on body fat in female rats. Rats were left untreated (intact) or ovariectomized (OVX), and were treated with 0, 0.1, 0.3, 0.5, 0.75 1.0 and 3.0 mg/day of compound NI, or treated with DHT or bicalutamide, and the percent change in body fat was deteimihed.
- Figure 3 Effect of Compound NI on body weight in female rats. Rats were left untreated (intact) or ovariectomized (ONX), and were treated with 0, 0.1, 0.3, 0.5, 0.75 1.0 and3.0mg/day of compound VI, ortreatedwith DHT or bicalutamide, and the body weight was determined. DETAILED DESCRIPTION OF THE INVENTION
- This invention relates to the prevention and " treatment of obesity. More particularly, this invention relates to a method of a) treating, preventing, suppressing, inhibiting, or reducing obesity; b) promoting, increasing or facilitating weight loss; c) decreasing, suppressing, inhibiting or reducing appetite; d) altering the body composition; e) altering lean body mass or fat free body mass; f) converting fat to lean muscle; g) treating, preventing, suppressing, inhibiting, or reducing an obesity-associated metaboUc disorder, for example hypertension, osteoarthritis, Type II diabetes meUitus, increased blood pressure, stroke, or heart disease; h) decreasing, suppressing, inhibiting or reducing adipogenesis; i) altering stem cell differentiation; and or j) altering the level of leptin; comprising administering a therapeutically effective amount of a selective androgen receptor modulator and/or its analog, derivative, isomer, metabolite, pharmaceuticaUy acceptable salt
- SARM compounds are a novel class of androgen receptor targeting agents ("ARTA"). that have previously been shown to be useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual Ubido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d)
- ADAM Androgen receptor targeting agents
- SARM compounds are useful for treating, preventing, suppressing, inhibiting or reducing the incidence of obesity and/or an obesity-associated metabolic disorder, controlling appetite and promoting weight loss, altering body composition including lean body mass and fat firee body mass, converting fat to lean muscle, blocking adipogenesis, altering stem cell differentiation and/or altering the level of leptin.
- SARM compounds are particularly useful in treating subjects suffering from symptoms and signs caused by obesity, excessive appetite and overweight, and obesity- associated metaboUc disorders such as hypertension, osteoarthritis, Type II diabetes meltitus, increased blood pressure, stroke, and heart disease.
- this- invention relates to a method of treating a subject suffering from obesity, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceuticaUy acceptable salt, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to treat obesity in the subj ect.
- SARM selective androgen receptor modulator
- this invention relates to a method of preventing, suppressing, inhibiting or reducing the incidence of obesity in a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metaboUte, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to prevent, suppress, inhibit or reduce the incidence of obesity in the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of promoting, increasing or facilitating weight loss in a subject, comprising the step of aclministering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N- oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to promote, increase or faciUtate weight loss in the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of decreasing, suppressing, inhibiting or reducing appetite of a subject, comprising the step of administering to the subj ect a selective androgen receptor modulator (S RM) and/or its analog, derivative, isomer, metabolite, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to decrease, suppress, inhibit or reduce the appetite of the subject.
- S RM selective androgen receptor modulator
- this invention relates to a method of altering the body composition of a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metaboUte, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to alter the body composition of the subj ect.
- SARM selective androgen receptor modulator
- altering the body composition comprises altering the lean body mass, the fat free body mass of the subject, or a combination thereof.
- this invention relates to a method of altering lean body mass or fat free body mass of a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N- oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to alter the lean body mass or fat free body mass of the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of converting fat to lean muscle in a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metaboUte, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to convert fat to lean muscle in the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of treating an obesity- associated metabolic disorder in a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metaboUte, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N- oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to treat the obesity-associated metabolic disorder in the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of preventing, suppressing, inhibiting or reducing an obesity-associated metabolic disorder in a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to prevent, suppress, inhibit or reduce the obesity-associated metabolic disorder in the subject.
- SARM selective androgen receptor modulator
- the obesity-associated metaboUc disorder is hypertension.
- the disorder is osteoarthritis.
- the disorder is Type II diabetes meUitus.
- the disorder is increased blood pressure.
- the disorder is stroke.
- the disorder is heart disease.
- this invention relates to a method of decreasing, suppressing, inhibiting or reducing adipogenesis in a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metaboUte, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to decrease, suppress, inhibit or reduce adipogenesis in the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of altering stem ceU differentiation in a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to alter stem ceU differentiation in the subject.
- SARM selective androgen receptor modulator
- this invention relates to a method of altering the level of leptin in a subject, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metaboUte, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to alter the level of leptin in the subject.
- SARM selective androgen receptor modulator
- altering the level of leptin comprises decreasing the level of leptin in the subject.
- this invention relates to a method of decreasing, suppressing, inhibiting or reducing the level of leptin in a subj ect, comprising the step of administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof, in an amount effective to decrease, suppress, inhibit or reduce the level of leptin in the subj ect.
- SARM selective androgen receptor modulator
- G is O or S
- X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
- T is OH, OR, -NHCOCH 3 , or NHCOR
- Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
- Y is CF 3 , F, I, Br, Cl, CN, CR 3 or SnR 3 ;
- Q is alkyl, F, Cl, Br, I, CF 3 , CN CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSRNHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR, NCS, SCN, NCO, OCN; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:
- R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, aUcenyl or OH; and
- Ri is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 .
- the SARM is an analog of the compound of formula I. In another embodiment, the SARM is a derivative of the compound of formula! In another embodiment, the SARM is an isomer of the compound of formula I. In another embodiment, the SARM is a metaboUte of the compound of formula I. In another embodiment, the SARM is a pharmaceuticaUy acceptable salt of the compound of formula I. In another embodiment, the SARM is a pharmaceutical product of the compound of formula I. In another embodiment, the SARM is a hydrate of the compound of formula I. In another embodiment, the SARM is an N-oxide of the compound of formula I. In another embodiment, the SARM is a crystal of the compound of formula I.
- the SARM is a polymorph of the compound of formula I.
- the SARM is a prodrug of the compound of formula I.
- the SARM is a combination of any of an analog, derivative, metaboUte, isomer, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of the compound of formula I.
- the SARM compound is a compound of formula I wherein X is O.
- the SARM compound is a compound of formula I wherein G is O.
- the SARM compound is a compound of formula I wherein Z is NO 2 .
- the SARM compound is a compound of formula I wherein Z is CN.
- the SARM compound is a compound of formula I wherein Y is CF 3 .
- the SARM compound is a compound of formula I wherein Q is NHCOCH . ha another embodiment, the SARM compound is a compound of formula I wherein Q is F.
- the SARM compound is a compound of formula I wherein T is OH.
- the SARM compound is a compound of formula I wherein Ri is CH 3 .
- the substituents Z and Y can be in any position of the ring carrying these substituents (hereinafter "A ring").
- the substituent Z is in the para position of the A ring.
- the substituent Y is in the meta position of the A ring.
- the substituent Z is in the para position of the A ring and substituent Y is in the meta position of the A ring.
- the substituent Q can be in any position of the ring carrying this substituent (hereinafter "B ring"). In one embodiment, the substituent Q is in the para position of the B ring. In another embodiment, the substituent Q is NHCOCH 3 and is in the para position of the B ring. In another embodiment, the substituent Q is F and is in the para position of the B ring.
- X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
- Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
- Y is CF 3 , F, I, Br, Cl, CN, CR 3 or SnR 3 ;
- Q is alkyl, F, Cl, Br, I, CF 3 , CN CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSRNHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,NCS, SCN,NCO, OCN; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C: c
- R is aUyl, haloalkyl, dihaloaUcyl, trihaloaUcyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, aUcenyl or OH.
- the SARM is an analog of the compound of formula II.
- the SARM is a derivative of the compound of formula EL hi another embodiment, the SARM is an isomer of the compound of formula II.
- the SARM is a metaboUte of the compound of formula II.
- the SARM is a pharmaceuticaUy acceptable salt of the compound of formula ⁇ .
- the SARM is a pharmaceutical product of the compound of formula II.
- the SARM is a hydrate of the compound of formula II.
- the SARM is an N-oxide of the compound of formula II.
- the SARM is a crystal of the compound of formula II.
- the SARM is a polymorph of the compound of formula II. In another embodiment, the SARM is a prodrug of the compound of formula II. In another embodiment, the SARM is a combination of any of an analog, derivative, metaboUte, isomer, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of the compound of formula II.
- the SARM compound is a compound of formula II wherein X is O. In another embodiment, the SARM compound is a compound of formula II wherein Z is NO 2 . In another embodiment, the SARM compound is a compound of formula II wherein Z is CN. In another embodiment, the SARM compound is a compound of formula II wherein Y is CF3. In another embodiment, the SARM compound is a compound of formula II wherein Q is NHCOCH 3 . In another embodiment, the SARM compound is a compound of formula II wherein Q is F.
- X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
- Ri is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
- T is OH, OR, -NHCOCH 3 , or NHCOR;
- R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
- A is a ring selected from:
- X)AY r B is a ring selected from: wherein A and B cannot simultaneously be a benzene ring; Z is NO 2 , CN, COOH, COR, NHCOR or CONHR; Y is CF 3 , F, I, Br, Cl, CN CR 3 or SnR 3 ; Qi and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSRNHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR, NCS, SCN, NCO, OCN,
- Q 3 and Q 4 are independently of each other ahydrogen, alkyl, F, Cl, Br, I, CF 3 , CN CR 3 , SnR 3 , NR 2 , NHCOCH3, NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, ' OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSRNHSO 2 CH 3 ,NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR, NCS, SCN, NCO or OCN;
- Wi O, NH, NR, NO or S;
- W 2 is N or NO.
- the SARM is an analog of the compound of formula HI. In another embodiment, the SARM is a derivative of the compound of formula HI. In another embodiment, the SARM is an isomer of the compound of formula HI. In another embodiment, the SARM is a metaboUte of the compound of formula HI. In another embodiment, the SARM is a pharmaceuticaUy acceptable salt of the compound of formula HI. In another embodiment, the SARM is a pharmaceutical product of the compound of formula HI. In another embodiment, the SARM is a hydrate of the compound of formula HI. In another embodiment, the SARM is an N-oxide of the compound of formula HI. In another embodiment, the SARM is a crystal of the compound of formula HI.
- the SARM is a polymorph of the compound of formula HI. In another embodiment, the SARM is a prodrug of the compound of formula HI. In another embodiment, the SARM is a combination of any of an analog, derivative, metaboUte, isomer, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of the compound of formula HI.
- the SARM compound is a compound of formula HI wherein X is O. In another embodiment, the SARM compound is a compound of formula HI wherein G is O. In another embodiment, the SARM compound is a compound of formula I wherein T is OH. In another embodiment, the SARM compound is a compound of formula HI wherein Ri is CH3. In another embodiment, the SARM compound is a compound of formula HI wherein Z is NO 2 . In another embodiment, the SARM compound is a compound of formula HI wherein Z is CN. In another embodiment, the SARM compound is a compound of formula HI wherein Y is CF 3 . In another embodiment, the SARM compound is a compound of formula HI wherein Qi is NHCOCH3. In another embodiment, the SARM compound is a compound of formula HI wherein Qi is F.
- the substituents Z and Y can be in any position of the ring carrying these substituents (hereinafter "A ring").
- the substituent Z is in the para position of the A ring.
- the substituent Y is in the meta position of the A ring.
- the substituent Z is in the para position of the A ring and substituent Y is in the meta position of the A ring.
- the substituents Qi and Q 2 can be in any position of the ring carrying these substituents (hereinafter "B ring").
- the substituent Qi is in the para position of the B ring.
- the subsituent is Q 2 is H.
- the substituent Qi is in the para position of the B ring and the subsituent is Q 2 is H.
- the substituent Qi is NHCOCH 3 and is in the para position of the B ring, and the substituent is Q 2 is H.
- the substitutent Qi is F and is in the para position of the B ring, and the substituent Q 2 is H.
- X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
- T is OH, OR, -NHCOCH3, or NHCOR;
- R is alkyl, haloalkyl, dihaloaUcyl, trihaloaUcyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
- Ri is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
- R 2 is F, Cl, Br, I, CH 3 , CF 3 , OH, CN, NO 2 , NHCOCH3, NHCOCF3, NHCOR, alkyl, aiylalkyl, OR, NH 2 , NHR, NR or SR;
- R 3 is F, Cl, Br, I, CN, NO 2 , COR, COOH, CONHR, CF 3 , SnR 3 , or R 3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:
- Z is NO 2 , CN, COR, COOH, or CONHR;
- Y is CF 3> F, Br, Cl, I, CN, or SnR 3 ;
- Q is H, alkyl, F, Cl, Br, I, CF 3 , CN CR 3 , SnR 3 , NR 2 , NHCOCH3, N ⁇ COCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHSO 2 CH 3 , NHSO 2 R, OH, OR, COR, OCOR, OSO 2 R, SO 2 R, SR, NCS, SCN, NCO, OCN; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:
- the SARM is an analog of the compound of formula IV. In another embodiment, the SARM is a derivative of the compound of formula IV. In another embodiment, the SARM is an isomer of the compound of formula IV. In another embodiment, the SARM is a metaboUte of the compound of formula IV. In another embodiment, the SARM is a pharmaceuticaUy acceptable salt of the compound of formula IV. In another embodiment, the SARM is a pharmaceutical product of the compoimd of formula IV. In another embodiment, the SARM is a hydrate of the compoimd of formula IV. In another embodiment, the SARM is an N-oxide of the compound of formula IV. In another embodiment, the SARM is a crystal of the compound of formula IV.
- the SARM is a polymorph of the compound of formula IV. In another embodiment, the SARM is a prodrug of the compound of formula IV. In another embodiment, the SARM is a combination of any of an analog, derivative, metaboUte, isomer, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of the compound of formula IV.
- the SARM compound is a compound of formula IV wherein X is 0. In another embodiment, the SARM compound is a compound of formula IV wherein G is O. In another embodiment, the SARM compound is a compound of formula
- the SARM compound is a compound of formula IN wherein Z is ⁇ O 2 .
- the SARM compound is a compound of formula IN wherein Z is C ⁇ .
- the SARM compound is a compound of formula IN wherein Y is CF 3 .
- the SARM compound is a compound of formula IN wherein Q is ⁇ HCOCH 3 .
- the SARM compound is a compound of formula IN wherein Q is F.
- the SARM compound is a compound of formula IN wherein T is
- the SARM compound is a compound of formula IV wherein
- Ri is CH 3 .
- the SARM compound is a compound of formula IV wherein Q is F and R 2 is CH 3 .
- the SARM compound is a compound of formula IV wherein Q is F and R 2 is Cl.
- the substituents Z, Y and R 3 can be in any position of the ring carrying these substituents (hereinafter "A ring").
- a ring the substituent Z is in the para position of the A ring.
- the substituent Y is in the meta position of the A ring.
- the substituent Z is in the para position of the A ring and substituent Y is in the meta position of the A ring.
- the substituents Q and R 2 can be in any position of the ring carrying these substituents (hereinafter "B ring").
- the substitutent Q is in the para position of the B ring.
- the substitutent Q is in the para position of the B ring.
- the substitutent Q is NHCOCH 3 and is in the para position of the B ring.
- the substituents R 2 and R 3 are not limited to one particular substituent, and can be any combination of the substituents Usted above.
- R 2 is F, Cl, Br, I, CH 3 , CF 3 , OH, CN, NO 2 , NHCOCH 3 ,
- NHCOCF 3 NHCOR, alkyl, arylaU yl, OR, NH 2 , NHR, NR 2 or SR;
- R 3 is F, Cl, Br, I, CN, NO 2 , COR, COOH, CONHR, CF 3 , S11R3, or R3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:
- R is aUcyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, aUcenyl or OH;
- Z is NO 2 , CN, COR, COOH, or CONHR;
- Y is CF 3 , F, Br, Cl, I, CN, or SnR 3 ;
- Q is H, alkyl, F, Cl, Br, I, CF 3 , CN CR 3 , SnR 3 , NR 2 , NHCOCH3, NHCOCF 3 , NHCORi NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF3, NHCSRNHSO 2 CH 3 , NHSO 2 R, OH, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,NCS, SCN, NCO, OCN; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:
- the SARM is an analog of the compound of formula V. In another embodiment, the SARM is a derivative of the compound of formula V. In another embodiment, the SARM is an isomer of the compound of formula V. In another embodiment, the SARM is a metabolite of the compound of formula V. In another embodiment, the SARM is a pharmaceutically acceptable salt of the compound of formula V. In another embodiment, the SARM is a pharmaceutical product of the compound of formula V. In another embodiment, the SARM is a hydrate of the compound of formula V. In another embodiment, the SARM is an N-oxide of the compound of formula V. In another embodiment, the SARM is a crystal of the compound of formula V.
- the SARM is a polymorph of the compound of formula V. In another embodiment, the SARM is a prodrug of the compound of formula V. In another embodiment, the SARM is a combination of any of an analog, derivative, metaboUte, isomer, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, N- oxide, crystal, polymorph or prodrug of the compound of formula V.
- the SARM is a compound of formula V wherein Z is NO 2 . In another embodiment, the SARM is a compound of formula V wherein Z is CN. In another embodiment, the SARM is a compound of formula V wherein Y is CF 3 . In another embodiment, the SARM is a compound of formula V wherein Q is NHCOCH 3 . In another embodiment, the SARM is a compound of formula V wherein Q is F. In another embodiment, the SARM is a compound of formula V wherein Q is F and R 2 is CH 3 . In another embodiment, the SARM is a compound of formula V wherein Q is F and R 2 is Cl.
- the substituents Z, Y and R 3 can be in any position of the A ring, and the substituents Q and R 2 can be in any position of B ring, as discussed above for compound IV. Furthermore, as discussed above, when the integers m and n are greater than one, the substituents R and R 3 are not limited to one particular substituent, and can be any combination of the substituents Usted above.
- the SARM is an analog of the compound of formula VI. In another embodiment, the SARM is a derivative of the compound of formula VI. In another embodiment, the SARM is an isomer of the compound of formula V! In another embodiment, the SARM is a metaboUte of the compound of formula VI. In another embodiment, the SARM is a pharmaceuticaUy acceptable salt of the compound of formula VI. In another embodiment, the SARM is a pharmaceutical product of the compound of formula VI. In another embodiment, the SARM is a hydrate of the compound of formula VI. In another embodiment, the SARM is an N-oxide of the compound of formula VI. In another embodiment, the SARM is a crystal of the compound of formula VI.
- the SARM is a polymorph of the compound of formula VI.
- the SARM is a prodrug of the compound of formula VI.
- the SARM is a combination of any of an analog, derivative, metaboUte, isomer, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of the compound of formula VI.
- the SARM is an analog of the compound of formula VH. In another embodiment, the SARM is a derivative of the compound of formula VH. In another embodiment, the SARM is an isomer of the compound of formula VH. In another embodiment, the SARM is a metaboUte of the compound of formula VH. In another embodiment, the SARM is a pharmaceuticaUy acceptable salt of the compound of formula VH. In another embodiment, the SARM is a pharmaceutical product of the compound of formula VH. In another embodiment, the SARM is a hydrate of the compound of formula VH. In another embodiment, the SARM is an ⁇ -oxide of the compound of formula VH. In another embodiment, the SARM is a crystal of the compound of formula VH.
- the SARM is a polymorph of the compound of formula VH.
- the SARM is a prodrug of the compound of formula VH.
- the SARM is a combination of any of an analog, derivative, metaboUte, isomer, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, ⁇ -oxide, crystal, polymorph or prodrug of the compound of formula VH.
- the substituent R is defined herein as an aUcyl, haloaUcyl, dihaloaU yl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl, or hydroxyl (OH).
- an "aUcyl” group refers to a saturated aUphatic hydrocarbon, including straight- chain, branched-chain and cyclic alkyl groups.
- the aUcyl group has 1- 12 carbons.
- the alkyl group has 1-7 carbons.
- the alkyl group has 1-6 carbons.
- the aUcyl group has 1-4 carbons.
- the alkyl group may be unsubstituted or substituted by one or more groups selected from halogen (e.g.
- haloalkyl group refers to an alkyl group as defined above, which is substituted by one or more halogen atoms, e.g. by F, Cl, Br or !
- halogen refers to elements of Group NH or the periodic table, e.g. F, Cl, Br or I.
- aryl group refers to an aromatic group having at least one carbocycUc aromatic group or heterocycUc aromatic group, which may be unsubstituted or substituted by one or more groups selected from halogen (e.g. F, Cl, Br, I), haloalkyl, hydroxy, alkoxy carbonyl, amido, alkylamido, dialkylamido, nitro, amino, alkylamino, diaUcylamino, carboxy or thio or thioa cyl.
- halogen e.g. F, Cl, Br, I
- aryl rings are phenyl, naph ⁇ hyl, pyranyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyrazolyl, pyridinyl, furanyl, fhiophenyl, thiazolyl, imidazolyl, isoxazolyl, and the like.
- a "hydroxyl” group refers to an OH group.
- An “alkenyl” group refers to a group having at least one carbon to carbon double bond.
- arylalkyl refers to an alkyl bound to an aryl, wherein aUcyl and aryl are as defined above.
- An example of an araUcyl group is a benzyl group.
- the present invention relates to the use of a SARM compound and/or its analog, derivative, isomer, metaboUte, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, ⁇ -oxide, prodrug, polymorph or crystal or combinations thereof.
- the invention relates to the use of an analog of the SARM compound.
- the invention relates to the use of a derivative of the SARM compound.
- the invention relates to the use of an isomer of the SARM compound.
- the invention relates to the use of a metabolite of the SARM compound.
- the invention relates to the use of a pharmaceuticaUy acceptable salt of the SARM compound, hi another embodiment, the invention relates to the use of a pharmaceutical product of the SARM compound. In another embodiment, the invention relates to the use of a hydrate of the SARM compound. In another embodiment, the invention relates to the use of an N-oxide of the SARM compound. In another embodiment, the invention relates to the use of aprodrug of the SARM compound. In another embodiment, the invention relates to the use of a polymorph of the SARM compound. In another embodiment, the invention relates to the use of a crystal of the SARM compound.
- the invention relates to the use of any of a combination of an analog, derivative, isomer, metabolite, pharmaceuticaUy acceptable salt, pharmaceutical product, hydrate, or N- oxide, prodrug, polymorph or crystal of the SARM compounds of the present invention.
- the term “isomer” includes, but is not limited to, optical isomers and analogs, structural isomers and analogs, conformational isomers and analogs, and the like.
- this invention encompasses the use of various optical isomers of the SARM compounds.
- the SARM compounds of the present invention contain at least one chiral center. Accordingly, the SARM compounds used in the methods of the present invention may exist in, and be isolated in, optically-active or racemic forms. Some compounds may also exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereroisomeric form, or mixtures thereof, which form possesses properties useful in the treatment of obesity and related disorders as described herein.
- the SARM compounds are the pure (R)-isomers.
- the SARM compounds are the pure (S)-isomers. In another embodiment, the SARM compounds are a mixture of the (R) and the (S) isomers. In another embodiment, the SARM compounds are a racemic rnixture comprising an equal amount of the (R) and the (S) isomers. It is weU known in the art how to prepare optically-active forms (for example, by resolution of the racemic form by recrystaUization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase).
- the invention includes pharmaceuticaUy acceptable salts of amino-substituted compounds with organic and inorganic acids, for example, citric acid and hydrochloric acid.
- the invention also includes N-oxides of the amino substituents of the compounds described herein.
- PharmaceuticaUy acceptable salts can also be prepared from the phenolic compounds by treatment with inorganic bases, for example, sodium hydroxide.
- esters of the phenoUc compounds can be made with aUphatic and aromatic carboxyUc acids, for example, acetic acid and benzoic acid esters.
- This invention further includes derivatives of the SARM compounds.
- derivatives includes but is not limited to ether derivatives, acid derivatives, amide derivatives, ester derivatives and the like.
- this invention further includes hydrates of the SARM compounds.
- hydrate includes but is not limited to hemihydrate, monohydrate, dihydrate, trihydrate and the like.
- This invention further includes pharmaceutical products of the SARM compounds.
- pharmaceutical product means a composition suitable for pharmaceutical use (pharmaceutical composition), as defined herein.
- This invention further includes prodrugs of the SARM compounds.
- prodrug means a substance which can be converted in-vivo into a biologically active agent by such reactions as hydrolysis, esterification, desterification, activation, salt formation and the Uke.
- This invention further includes crystals of the SARM compounds.
- this invention provides polymorphs of the SARM compounds.
- crystal means a substance in a crystalline state.
- polymorph refers to a particular crystalline state of a substance, having particular physical properties such as X-ray diffraction, IR spectra, melting point, and the like.
- SARM compounds are a novel class of androgen receptor targeting agents ("ARTA"), that have previously been shown to be useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased Ubido, sexual dysfunction, erectUe dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual Ubido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia favorhair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment of a variety of hormone-related conditions, for example conditions
- SARM compounds are also useful for a) treating, preventing, suppressing, inhibiting, or reducing obesity; b) promoting, increasing or faciUtating weight loss; c) decreasing, suppressing, inhibiting or reducing appetite; d) altering the body composition; e) altering lean body mass or fat free body mass; f) converting fat to lean muscle; g) treating, preventing, suppressing, inhibiting, or reducing an obesity-associated metaboUc disorder, for example hypertension, osteoarthritis, Type H diabetes meUitus, increased bloodpressure, stroke, or heart disease; h) decreasing, suppressing, inhibiting or reducing adipogenesis; i) altering stem cell differentiation; and/or j) altering the level of leptin; comprising administering a therapeutically effective amount of a selective androgen receptor modulator and/or its analog, derivative, isomer, metaboUte, pharmaceuticaUy acceptable salt, pharmaceutical
- the SARM compounds of the present invention alter the levels of leptin in a subj ect.
- the SARM compounds decrease the levels of leptin and are therefore inhibitors of leptin.
- the SARM compounds of the present invention increase the levels of leptin in a subject.
- leptin was shown to have an effect on appetite on weight loss in obese mice, and thus has been implicated in obesity (PeUeymounter et al., 1995, Halaas et al., 1995, Campfield et al., 1995).
- leptin When leptin was injected into grossly obese mice, which possessed two mutant copies of the ob gene, the mice exhibited a reduced appetite and began to lose weight. In addition, leptin played a role in reducing the animals' food intake and in increasing their energy expenditure. Similarly, when normal mice received leptin, they also ate less than the untreated controls. Moreover, it has been suggested by Campfield et al that leptin acts on central neuronal networks to regulate feeding behavior and energy balance.
- the term 'leptin inhibitor' refers to a SARM compound which decreases the level of leptin, so that the level of leptin after treatment with the SARM compound is lower than the level of leptin in the absence of the compoimd.
- 'increasing the level of leptin' means that the levels of leptin after treatment with the SARM compound is higher than the level of leptin in the absence of the SARM compound.
- the term 'level of leptin' refers to the serum level of leptin.
- the SARM compounds of the present invention have an effect on leptin in-vitro and in-vivo.
- Leptin levels can be measured by methods known to one skilled in the art, for example by commercially available ELISA kits. In addition, Leptin levels may be determined in in-vitro assays, or in in-vivo assays, by any method known to a person skilled in the art.
- leptin Since leptin is impUcated in controlling appetite, weight loss, food intake, and energy expenditure, modulating and/or controUing the levels of leptin is a useful therapeutic approach in treating preventing, inhibiting or reducing the incidence of obesity in subjects suffering from obesity. Modulating the level of leptin can result in a loss of appetite, a reduction of food intake, and an increase in energy expenditure in the subject, and thus may contribute to the control and treatment of obesity.
- the term "obesity" is defined as an increase in body weight beyond the limitation of skeletal and physical requirement, as the result of excessive accumulation of fat in the body.
- osteoarthritis a disorder which results from, is a consequence of, is exacerbated by or is secondary to obesity.
- Non-limiting examples of such a disorder are osteoarthritis, Type H diabetes meUitus, increased blood pressure, stroke, and heart disease.
- osteoarthritis refers to a non-inflammatory degenerative joint disease occurring chiefly in older people, characterized by degeneration of the articular cartilage, hypertrophy of bones and the margins and changes in the synovia! membrane. It is accompanied by pain and stiffness, particularly after prolonged activity.
- diabetes means a relative or absolute lack of insulin leading to uncontrolled carbohydrate metabolism. Most patients can be clinically classified as having either insulin-dependent diabetes mellitus (IDDM or Type-I diabetes) or non- insulin-dependent diabetes meUitus (NIDDM or Type-H diabetes).
- IDDM insulin-dependent diabetes mellitus
- NIDDM non- insulin-dependent diabetes meUitus
- IPDDM insulin-dependent diabetes meUitus
- IPDDM non- insulin-dependent diabetes meUitus
- the term “increased blood pressure” or “hypertension” refers to a repeatedly high blood pressure above 140 over 90 mmHg. Chronically high blood pressure can cause blood vessel changes in the back of the eye, thickening of the heart muscle, kidney f-rilure, and brain damage.
- stroke refers to damage to nerve cells in the brain due to insufficient blood supply often caused by a bursting blood vessel or a blood clot.
- heart disease refers to a malfunction in the heart normal function and activity, including heart failure.
- adipogenesis also referred to as “lipogenesis” refers to the production of fat, either fatty degeneration or fatty infiltration, and also covers the normal deposition of fat or the conversion of carbohydrate or protein to fat.
- stem ceU refers to a cell that gives rise to a lineage of cells. In the process of stem cells differentiation, these ceUs divide to produce dissimilar daughter ceUs, one replacing the original stem cell, the other differentiating further to different lineages of cells.
- the SARMs which are useful in preventing and treating obesity are classified as androgen receptor agonists (AR agonists) or androgen receptor antagonists (AR antagonists).
- AR agonists androgen receptor agonists
- AR antagonists androgen receptor antagonists
- the AR is a ligand-activated transcriptional regulatory protein that mediates induction of male sexual development and function through its activity with endogenous androgens (male sex hormones).
- the androgenic hormones are steroids which are produced in the body by the testis and the cortex of the adrenal gland. Androgenic steroids play an important role in many physiologic processes, including the development and maintenance of male sexual characteristics such as muscle and bone mass, prostate growth, spermatogenesis, and the male hair pattern (Matsumoto, Endocrinol. Met. Clin. N.
- the endogenous steroidal androgens include testosterone and dihydrotestosterone ("DHT").
- DHT dihydrotestosterone
- Other steroidal androgens include esters of testosterone, such as the cypionate, propionate, phenylpropionate, cyclopentylpropionate, isocarporate, enanthate, and decanoate esters, and other synthetic androgens such as 7-Methyl- Nortestosterone ("MENT”) and its acetate ester (Sundaram et al., "7 Alpha-Methyl- Nortestosterone(MENT): The Optimal Androgen For Male Contraception," Ann. Med., 25:199-205 (1993) (“Sundaram”)).
- a receptor agonist is a substance which binds receptors and activates them.
- a receptor antagonist is a substance which binds receptors and inactivates them.
- the SARMs which are useful in treating and preventing obesity and which modulate leptin levels are AR agonists, and are, therefore, useful in binding to and activating the AR.
- the SARMs which are useful in treating and preventing obesity and which modulate leptin levels are AR antagonists, and are, therefore, useful in binding to and inactivating the AR.
- Assays to determine whether the compounds of the present invention are AR agonists or antagonists are well known to a person skilled in the art.
- AR agonistic activity can be determined by monitoring the ability of the SARM compounds to maintain and/or stimulate the growth of AR containing tissue such as prostate and seminal vesicles, as measured by weight.
- AR antagonistic activity can be determined by monitoring the ability of the SARM compounds inhibit the growth of AR containing tissue.
- the SARM compounds of the present invention can be classified as partial AR agonist/antagonists.
- the SARMs are AR agonists in some tissues, to cause increased transcription of AR-responsive genes (e.g. muscle anabolic effect). In other tissues, these compounds serve as competitive inhibitors of testosterone/DHT on the AR to prevent agonistic effects of the native androgens.
- the compounds of the present invention bind either reversibly or irreversibly to the androgen receptor.
- the SARM compounds bind reversibly to the androgen receptor.
- the SARM compounds bind irreversibly to the androgen receptor.
- the compounds of the present invention may contain a functional group (affinity label) that allows aU ylation of the androgen receptor (i.e. covalent bond formation).
- a functional group affinity label
- contacting means that the SARM compound of the present mvention is introduced into a sample containing the protein or enzyme in a test tube, flask, tissue culture, chip, array, plate, microplate, capillary, or the like, and incubated at a temperature and time sufficient to permit binding of the SARM to the enzyme.
- Methods for contacting the samples with the SARM or other specific binding components are known to those skilled in the art and may be selected depending on the type of assay protocol to be run. Incubation methods are also standard and are known to those skilled in the art.
- the treatment methods of the present invention comprise, in one embodiment, administering a pharmaceutical preparation comprising the SARM compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymoi h, crystal or any combination thereof; and a pharmaceutically acceptable carrier.
- pharmaceutical composition means a composition comprising an "effective amount" of the active ingredient, i.e. the SARM compound, together with a pharmaceutically acceptable carrier or diluent.
- an “effective amount” as used herein refers to that amount which provides a therapeutic effect for a given condition and administration regimen.
- An “effective amount” of the SARM compounds as used herein can be in the range of 1-500 mg/day. In one embodiment the dosage is in the range of 1 -100 mg/day. In another embodiment the dosage is in the range of 100-500 mg/day. In another embodiment the dosage is in a range of 45-60 mg/day. In another embodiment the dosage is in the range of 15-25 mg/day. In another embodiment the dosage is in the range of 55-65 mg/day. In another embodiment the dosage is in the range of 45-60 mg/day.
- the SARM compounds can be administered daily, in single dosage forms containing the entire amount of daily dose, or can be administered daily in multiple doses such as twice daily or three times daUy.
- the SARM compounds can also be administered mtermittently, for example every other day, 3 days a week, four days a week, five days a week and the like.
- the term “treating” includes preventative as weU as disorder remitative treatment.
- the terms “reducing”, “suppressing” and “inhibiting” have their commonly understood meaning of lessening or decreasing.
- the term “facilitating” is giving its commonly understood meaning of increasing the rate.
- the term “promoting” is given its commonly understood meaning of increasing.
- progression means increasing in scope or severity, advancing, growing or becoming worse.
- administering refers to bringing a subject in contact with a SARM compound of the present invention.
- administration can be accomplished in vitro, i.e. in a test tube, or in vivo, i.e. in ceUs or tissues of living organisms, for example humans.
- the present mvention encompasses administering the compounds of the present invention to a subject.
- the subject is a mammalian subject. In another embodiment, the subject is a human.
- compositions containing the SARM agent can be administered to a subject by any method known to a person sldUed in the art, such as parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermaUy, subcutaneously, intraperitonealy, intraventricularly, intracranially, intravaginally or intratumoraUy.
- the pharmaceutical compositions are administered orally, and are thus formulated in a form suitable for oral administration, i.e. as a soUd or a Uquid preparation.
- Suitable solid oral formulations include tablets, capsules, pUls, granules, pellets and the like.
- Suitable Uquid oral formulations include solutions, suspensions, dispersions, emulstions, oils and the like.
- the SARM compounds are formulated in a capsule.
- the compositions of the present invention comprise in addition to the SARM active compound and the inert carrier or dUuent, a hard gelating capsule.
- the pharmaceutical compositions are at ninistered by intravenous, intraarterial, or intramuscular injection of a Uquid preparation.
- suitable liquid formulations include solutions, suspensions, dispersions, emulsions, oils and the tike.
- the pharmaceutical compositions are administered intravenously, and are thus formulated in a form suitable for intravenous administration.
- the pharmaceutical compositions are administered intraarterially, and are thus formulated in a form suitable for intraarterial administration.
- the pharmaceutical compositions are administered intramuscularly, and are thus formulated in a form suitable for intramuscular adininistration.
- the pharmaceutical compositions are a ⁇ ninistered topicaUy to body surfaces, and are thus formulated in a form suitable for topical administration.
- Suitable topical formulations include gels, ointments, creams, lotions, drops and the like.
- the SARM agents or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the tike are prepared and applied as solutions, suspensions, or emulsions in a physiologically acceptable diluent with or without a pharmaceutical carrier.
- the pharmaceutical compositions are administered as a suppository, for example a rectal suppository or a urethral suppository.
- the pharmaceutical compositions are administered by subcutaneous implantation of a pellet.
- the peUet provides for controlled release of SARM agent over a period of time.
- the active compound can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez- Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid).
- a liposome see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez- Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid).
- pharmaceuticalaUy acceptable carriers or diluents are well known to those skilled in the art.
- the carrier or dUuent may be a soUd carrier or diluent for solid formuations, a liquid carrier or diluent for Uquid formulations, or mixtures thereof.
- Solid carriers/diluents include, but are not limited to, a gum, a starch (e.g. corn starch, pregeletanized starch), a sugar (e.g., lactose, mannitol, sucrose, dextrose), a cellulosic material (e.g. microcrystalline cellulose), an acrylate (e.g. polymethylacrylate), calcium carbonate, magnesium oxide, talc, or mixtures thereof.
- a gum e.g. corn starch, pregeletanized starch
- a sugar e.g., lactose, mannitol, sucrose, dextrose
- a cellulosic material e.g. microcrystalline cellulose
- an acrylate e.g. polymethylacrylate
- calcium carbonate e.g. polymethylacrylate
- non-aqueous solvents examples include propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcohoUc/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, and fish-liver oil.
- Parenteral vehicles for subcutaneous, intravenous, intraarterial, or intramuscular injection
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the tike.
- Examples are sterile liquids such as water and oUs, with or without the addition of a surfactant and other pharmaceuticaUy acceptable adjuvants.
- Uquid carriers In general, water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycols or polyethylene glycol are preferred Uquid carriers, particularly for injectable solutions.
- oUs are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oU, mineral oil, olive oU, sunflower oil, and fish-liver oU.
- compositions may further comprise binders (e.g. acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl ceUulose, hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g.
- binders e.g. acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl ceUulose, hydroxypropyl methyl cellulose, povidone
- disintegrating agents e.g.
- cornstarch potato starch, alginic acid, silicon dioxide, croscarmelose sodium, crospovidone, guar gum, sodium starch glycolate), buffers (e.g., Tris-HCI, acetate, phosphate) of various pH and ionic strength, additives such as albumin, or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g.
- sodium lauryl sulfate permeation enhancers
- solubilizing agents e.g., glycerol, polyethylene glycerol
- anti-oxidants e.g., ascorbic acid, sodium metabisulfite, butylated hydroxyanisole
- stabilizers e.g. hydroxypropyl ceUulose, hyroxypropyhnethyl cellulose
- viscosity increasing agents e.g. carbomer, colloidal siUcon dioxide, ethyl ceUulose, guar gum
- sweetners e.g.
- aspartame, citric acid preservatives (e.g., Thimerosal, benzyl alcohol, parabens), lubricants (e.g. stearic acid, magnesium stearate, polyethylene glycol, sodium lauryl sulfate), flow-aids (e.g. coUoidal silicon dioxide), plasticizers (e.g. diethyl phthalate, triethyl citrate), emulsif ⁇ ers (e.g. carbomer, hydroxypropyl cellulose, sodium lauryl sulfate), polymer coatings (e.g., poloxamers or poloxarnines), coating and film forming agents (e.g. ethyl cellulose, acrylates, polymethacrylates) and/or adjuvants.
- lubricants e.g. stearic acid, magnesium stearate, polyethylene glycol, sodium lauryl sulfate
- flow-aids e.g. coUoidal silicon dioxide
- the pharmaceutical compositions provided herein are controlled release compositions, i.e. compositions in which the SARM compound is released over a period of time after administration.
- Controlled or sustained release compositions include formulation in UpophiUc depots (e.g. fatty acids, waxes, oUs).
- the composition is an immediate release composition, i.e. a composition in which all of the SARM compoimd is released immediately after administration.
- the pharmaceutical composition can be delivered in a controlled release system.
- the agent may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, Uposomes, or other modes of administration.
- a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Bio ed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989).
- polymeric materials can be used.
- a controlled release system can be placed in proximity to the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical AppUcations of Controlled
- compositions may also include incorporation of the active material into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycohc acid, hydrogels, etc, or onto Uposomes, microemulsions, miceUes, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts.)
- polymeric compounds such as polylactic acid, polglycohc acid, hydrogels, etc.
- Uposomes microemulsions, miceUes, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts.
- particulate compositions coated with polymers e.g. poloxamers or poloxamines
- the compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors are also comprehended by the mvention.
- Also comprehended by the invention are compounds modified by the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl ceUulose, dextran, polyvinyl alcohol, polyvinylpyrroUdone or polyproline.
- the modified compounds are known to exhibit substantiaUy longer half-lives in blood foUowing intravenous inj ection than do the corresponding unmodified compounds (Abuchowski et al., 1981 ; Newmark et al, 1982; and Katre et al., 1987).
- Such modifications may also increase the compound's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stabUity of the compound, and greatly reduce the immunogenicity and reactivity of the compound.
- the desired in vivo biological activity may be achieved by the administration of such polymer-compound abducts less frequently or in lower doses than with the unmodified compound.
- compositions which contain an active component are well understood in the art, for example by mixing, granulating, or tablet- forming processes.
- the active therapeutic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient.
- the SARM agents or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the tike are mixed with additives customary for this purpose, such as veliicles, stabilizers, or inert dUuents, and converted by customary methods into suitable forms for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic or oUy solutions.
- the SARM agents or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are converted hito a solution, suspension, or emulsion, if desired with the substances customary and suitable for this purpose, for example, solubilizers or other.
- An active component can be formulated into the composition as neutralized pharmaceutically acceptable salt forms.
- PharmaceuticaUy acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide or antibody molecule), which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
- the salts of the SARM wiU be pharmaceuticaUy acceptable salts.
- Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts.
- Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic: acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic: acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric
- the methods of the present invention comprise a ⁇ niimstering a SARM compound as the sole active ingredient.
- methods or treating obesity as disclosed herein which comprise adixiinistering the SARM compounds in combination with one or more therapeutic agents.
- agents include, hut are not limited to: LHRH analogs, reversible antiandrogens, antiestrogens, anticancer drugs, 5-alpha reductase inhibitors, aromatase inhibitors, progestins, or agents acting through other nuclear hormone receptors.
- the present invention provides compositions and pharmaceutical compositions comprising a selective androgen receptor modulator compound, in combination with an LHRH analog.
- the present invention provides compositions and pharmaceutical compositions comprising a selective androgen receptor modulator compound, in combination with a reversible antiandiO en.
- the present invention provides compositions and pharmaceutical compositions comprising a selective androgen receptor modulator compound, in combination with an antiestrogen.
- the present invention provides compositions and pharmaceutical compositions comprising a selective androgen receptor modulator compound, in combination with an anticancer drug.
- the present invention provides compositions and pharmaceutical compositions comprising a selective androgen receptor modulator compound, in combination with a 5-alpha reductase inhibitor. In another embodiment, the present invention provides compositions and pharmaceutical compositions comprising a selective androgen receptor modulator compound, in combination with an aromatase inhibitor. In another embodiment, the present invention provides compositions and pharmaceutical compositions comprising a selective androgen receptor modulator compound, in combination with a progestin. In another embodiment, the present invention provides compositions and pharmaceutical compositions comprising a selective androgen receptor modulator compound, in' combination with an agent acting through other nuclear hormone receptors.
- Immature male Sprague-Dawleyrats (195-205 gram body weight) were used for this study. Animals were divided into groups of 15 animals (5 animals per time point) to receive one of the following treatments: (1) vehicle control, (2) testosterone propionate dissolved m vehicle solution at a dose of 500 ⁇ g/day, (3) Compound VI at dose of 500 ⁇ g/day dissolved in vehicle solution, or (4) Compound VH at dose of 500 ⁇ g/day dissolved in vehicle solution. All doses were delivered by subcutaneous placement of Alzet osmotic pumps. DaUy food intake was recorded for one-week and two-week studies.
- Serum concentrations of testosterone (T), leptin, Insulin and IGF-1 were determined by commercially available ELISA kits. Serum concentration of Compound VI and Compoimd VH were determined by HPLC.
- Compound VH had a more profound effect on serum leptin concentrations, suggesting it may affect animal body composition and other endocrine systems, such as the hypo ⁇ halamo-pituitary-IGF-1 axis and the reproductive axis.
- Drug administration with Compound VI, bicalutamide (an antiandrogen), and/or DHT commenced on day 0 or 90 with the compound of interest administered via daily subcutaneous injection (0.20 mL) and continued until day 120 or 210 of the study.
- Drug solutions were prepared daily by dissolving in DMSO and dilution with PEG 300. The percentage of DMSO was the same in aU vehicles (17.6%), as determined based on the solubility of the test compounds.
- FIG. 1 A shows the percent change in lean body mass.
- Figure IB shows the absolute values of lean body mass (in grams).
- the high dose (3 mg/day) of Compound Nl-t eated group showed 9% increase in lean mass (Figure 1 A), as compared to the ovariectomized (OVX) control group at the 90 day time point. Similar trends were observed for aU dose groups.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41822902P | 2002-10-15 | 2002-10-15 | |
US418229P | 2002-10-15 | ||
PCT/US2003/032509 WO2004034978A2 (en) | 2002-10-15 | 2003-10-14 | Treating obesity with selective androgen receptor modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1558232A2 true EP1558232A2 (en) | 2005-08-03 |
EP1558232A4 EP1558232A4 (en) | 2008-07-02 |
Family
ID=32107907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03777596A Withdrawn EP1558232A4 (en) | 2002-10-15 | 2003-10-14 | Treating obesity with selective androgen receptor modulators |
Country Status (8)
Country | Link |
---|---|
US (1) | US20040224979A1 (en) |
EP (1) | EP1558232A4 (en) |
JP (1) | JP2006505563A (en) |
CN (1) | CN1726019A (en) |
AU (1) | AU2003287075A1 (en) |
CA (1) | CA2501797A1 (en) |
TW (1) | TW200413288A (en) |
WO (1) | WO2004034978A2 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7759520B2 (en) | 1996-11-27 | 2010-07-20 | University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
US7919647B2 (en) | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
US8445534B2 (en) | 2000-08-24 | 2013-05-21 | University Of Tennessee Research Foundation | Treating androgen decline in aging male (ADAM)-associated conditions with SARMs |
US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
US8853266B2 (en) * | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US20060276539A1 (en) * | 2002-10-16 | 2006-12-07 | Dalton James T | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS |
CN1726020A (en) * | 2002-10-16 | 2006-01-25 | Gtx公司 | Treating androgen decline in aging male (ADAM)-associated conditions with sarms |
US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
FI20030958A0 (en) * | 2003-06-27 | 2003-06-27 | Orion Corp | New compounds |
EA013738B1 (en) * | 2003-10-14 | 2010-06-30 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Treating bone-related disorders with selective androgen receptor modulators |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US7601725B2 (en) | 2004-07-16 | 2009-10-13 | Sunesis Pharmaceuticals, Inc. | Thienopyrimidines useful as Aurora kinase inhibitors |
JP2009506119A (en) * | 2005-08-31 | 2009-02-12 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | Treatment of kidney disease, burns, wounds and spinal cord injury using selective androgen receptor modulators |
JP5449775B2 (en) | 2005-10-19 | 2014-03-19 | チャバフ ピーティーワイ エルティーディー | Reduction of side effects with aromatase inhibitors used to treat breast cancer |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
CN103002737A (en) | 2010-01-11 | 2013-03-27 | Gtx公司 | Methods of treating meibomian gland dysfunction |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
DK2872482T3 (en) | 2012-07-13 | 2020-09-21 | Oncternal Therapeutics Inc | A PROCEDURE FOR TREATING BREAST CANCER WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
CA2964371A1 (en) * | 2014-10-16 | 2016-04-21 | Gtx, Inc. | Methods of treating urological disorders using sarms |
AU2015336929B2 (en) | 2014-10-22 | 2021-03-18 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
AU2016343297A1 (en) | 2015-10-22 | 2018-05-10 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
EP3976048A4 (en) | 2019-06-03 | 2023-07-12 | Havah Therapeutics Pty Ltd | Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020099036A1 (en) * | 2000-08-24 | 2002-07-25 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3875229A (en) * | 1972-11-24 | 1975-04-01 | Schering Corp | Substituted carboxanilides |
US4139638A (en) * | 1976-09-23 | 1979-02-13 | Schering Corporation | Methods for the treatment of hirsutism |
EP0002309B1 (en) * | 1977-10-12 | 1982-12-01 | Imperial Chemical Industries Plc | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them |
US4191775A (en) * | 1977-12-15 | 1980-03-04 | Imperial Chemical Industries Limited | Amide derivatives |
NZ197008A (en) * | 1980-05-22 | 1984-10-19 | Ici Ltd | Acylanilide derivatives and pharmaceutical compositions |
JPS57171904A (en) * | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
ATE28864T1 (en) * | 1982-07-23 | 1987-08-15 | Ici Plc | AMIDE DERIVATIVES. |
GB8617652D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Acylanilide derivatives |
US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US5609849A (en) * | 1994-03-11 | 1997-03-11 | The Trustees Of The University Of Pennsylvania | Serotonin (5-HT1A) receptor ligands and imaging agents |
US5656651A (en) * | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
US6071957A (en) * | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
WO1998053826A1 (en) * | 1997-05-30 | 1998-12-03 | The University Of Tennessee Research Corporation | Non-steroidal agonist compounds and their use in male hormone therapy |
WO1998055153A1 (en) * | 1997-06-04 | 1998-12-10 | The University Of Tennessee Research Corporation | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
EP1299094A2 (en) * | 2000-06-28 | 2003-04-09 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
US20030022868A1 (en) * | 2001-06-25 | 2003-01-30 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
AU2003287077B2 (en) * | 2002-10-15 | 2007-09-20 | University Of Tennessee Research Foundation | Methylene-bridged selective androgen receptor modulators and methods of use thereof |
-
2003
- 2003-10-14 US US10/683,160 patent/US20040224979A1/en not_active Abandoned
- 2003-10-14 CN CNA2003801061784A patent/CN1726019A/en active Pending
- 2003-10-14 WO PCT/US2003/032509 patent/WO2004034978A2/en active Application Filing
- 2003-10-14 EP EP03777596A patent/EP1558232A4/en not_active Withdrawn
- 2003-10-14 JP JP2004544888A patent/JP2006505563A/en active Pending
- 2003-10-14 AU AU2003287075A patent/AU2003287075A1/en not_active Abandoned
- 2003-10-14 CA CA002501797A patent/CA2501797A1/en not_active Abandoned
- 2003-10-15 TW TW092128561A patent/TW200413288A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020099036A1 (en) * | 2000-08-24 | 2002-07-25 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
Non-Patent Citations (1)
Title |
---|
See also references of WO2004034978A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2501797A1 (en) | 2004-04-29 |
JP2006505563A (en) | 2006-02-16 |
TW200413288A (en) | 2004-08-01 |
WO2004034978A2 (en) | 2004-04-29 |
CN1726019A (en) | 2006-01-25 |
US20040224979A1 (en) | 2004-11-11 |
WO2004034978A3 (en) | 2004-07-15 |
AU2003287075A1 (en) | 2004-05-04 |
EP1558232A4 (en) | 2008-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040224979A1 (en) | Treating obesity with selective androgen receptor modulators | |
AU2002364949B2 (en) | Treating muscle wasting with selective androgen receptor modulators | |
US7547728B2 (en) | Treating muscle wasting with selective androgen receptor modulators | |
US20050032750A1 (en) | Treating androgen deficiency in female (ADIF)-associated conditions with SARMS | |
AU2003287077B2 (en) | Methylene-bridged selective androgen receptor modulators and methods of use thereof | |
US6838484B2 (en) | Formulations comprising selective androgen receptor modulators | |
US9493403B2 (en) | Treating androgen decline in aging male (ADAM)-associated conditions with SARMs | |
US8008348B2 (en) | Treating muscle wasting with selective androgen receptor modulators | |
US20040138244A1 (en) | Heterocyclic selective androgen receptor modulators and methods of use thereof | |
MXPA04007639A (en) | Treating benign prostate hyperplasia with sarms. | |
US20050080054A1 (en) | Treating androgen decline in aging male (ADAM)-associated conditions with SARMS | |
US20060276539A1 (en) | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS | |
AU2007202324B2 (en) | Treating muscle wasting with selective androgen receptor modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050517 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1080002 Country of ref document: HK |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CHEN, JIYUN Inventor name: VEVERKA, KAREN, A. Inventor name: STEINER, MITCHELL, S. Inventor name: MILLER, DUANE, D. Inventor name: DALTON, JAMES, T. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080530 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20090130 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1080002 Country of ref document: HK |